CY1113403T1 - Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων - Google Patents

Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων

Info

Publication number
CY1113403T1
CY1113403T1 CY20121100924T CY121100924T CY1113403T1 CY 1113403 T1 CY1113403 T1 CY 1113403T1 CY 20121100924 T CY20121100924 T CY 20121100924T CY 121100924 T CY121100924 T CY 121100924T CY 1113403 T1 CY1113403 T1 CY 1113403T1
Authority
CY
Cyprus
Prior art keywords
monitoring
therapies
assessing
evolution
effectiveness
Prior art date
Application number
CY20121100924T
Other languages
Greek (el)
English (en)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of CY1113403T1 publication Critical patent/CY1113403T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
CY20121100924T 2007-10-24 2012-10-04 Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων CY1113403T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
EP08842581A EP2201376B1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
CY1113403T1 true CY1113403T1 (el) 2016-06-22

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100924T CY1113403T1 (el) 2007-10-24 2012-10-04 Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων
CY20151100234T CY1116089T1 (el) 2007-10-24 2015-03-06 Cd73 ως ενας βιοδεικτης για την παρακολουθηση της εξελιξης νοσων και εκτιμηση της αποτελεσματικοτητας θεραπειων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20151100234T CY1116089T1 (el) 2007-10-24 2015-03-06 Cd73 ως ενας βιοδεικτης για την παρακολουθηση της εξελιξης νοσων και εκτιμηση της αποτελεσματικοτητας θεραπειων

Country Status (14)

Country Link
US (1) US20100209942A1 (cg-RX-API-DMAC7.html)
EP (2) EP2201376B1 (cg-RX-API-DMAC7.html)
JP (2) JP4982610B2 (cg-RX-API-DMAC7.html)
KR (2) KR20100059902A (cg-RX-API-DMAC7.html)
CA (1) CA2702635A1 (cg-RX-API-DMAC7.html)
CY (2) CY1113403T1 (cg-RX-API-DMAC7.html)
DK (2) DK2201376T3 (cg-RX-API-DMAC7.html)
ES (2) ES2389751T3 (cg-RX-API-DMAC7.html)
FI (1) FI20070795A0 (cg-RX-API-DMAC7.html)
HR (2) HRP20120743T1 (cg-RX-API-DMAC7.html)
PL (2) PL2201376T3 (cg-RX-API-DMAC7.html)
PT (2) PT2503338E (cg-RX-API-DMAC7.html)
SI (2) SI2503338T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009053523A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
AU2011281012A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
EP2596132A4 (en) 2010-07-23 2013-12-18 Harvard College METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
MX2014015434A (es) 2012-06-15 2015-07-14 Harry Stylli Metodos para detectar enfermedades o condiciones utilizando celulas enfermas en circulacion.
PL2956772T3 (pl) * 2013-02-14 2018-12-31 Faron Pharmaceuticals Oy Sposób określenia biomarkerów związanych z zespołem ostrej niewydolności oddechowej (ARDS), sposób monitorowania rozwoju i leczenia ARDS u pacjenta
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
GB201706747D0 (en) * 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515965A (ja) * 1995-08-18 2002-05-28 ダブリュー． ランドリ，ドナルド 抗体触媒反応の調節による有機化合物の検出
EP0862652A1 (en) 1995-10-13 1998-09-09 IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
CA2439961A1 (en) * 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
US7534423B2 (en) 2003-03-28 2009-05-19 Faron Pharmaceuticals Oy Method for inducing an elevated level of adenosine in an individual
CA2528152A1 (en) * 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
JP2009505658A (ja) * 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
EP2021350B1 (en) * 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
EP2041574B1 (en) * 2006-07-14 2016-11-16 The Regents of The University of California Cancer biomarkers and methods of use threof

Also Published As

Publication number Publication date
PT2503338E (pt) 2015-03-05
WO2009053523A1 (en) 2009-04-30
CA2702635A1 (en) 2009-04-30
ES2532361T3 (es) 2015-03-26
EP2201376B1 (en) 2012-08-08
EP2503338B1 (en) 2014-12-24
JP5619810B2 (ja) 2014-11-05
PL2201376T3 (pl) 2013-01-31
SI2503338T1 (sl) 2015-06-30
US20100209942A1 (en) 2010-08-19
HRP20120743T1 (hr) 2012-10-31
EP2201376A1 (en) 2010-06-30
JP2012159514A (ja) 2012-08-23
EP2201376A4 (en) 2011-03-23
FI20070795A0 (fi) 2007-10-24
DK2201376T3 (da) 2012-10-15
JP4982610B2 (ja) 2012-07-25
ES2389751T3 (es) 2012-10-31
CY1116089T1 (el) 2017-02-08
PL2503338T3 (pl) 2015-06-30
EP2503338A2 (en) 2012-09-26
JP2011501176A (ja) 2011-01-06
KR20160029869A (ko) 2016-03-15
SI2201376T1 (sl) 2012-09-28
KR20100059902A (ko) 2010-06-04
DK2503338T3 (en) 2015-03-09
HRP20150181T1 (hr) 2015-06-19
EP2503338A3 (en) 2013-03-13
PT2201376E (pt) 2012-08-20

Similar Documents

Publication Publication Date Title
CY1113403T1 (el) Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων
EA201100965A1 (ru) Биомаркеры для ингибиторов с антиангиогенной активностью
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
CY1108829T1 (el) Ενεργοποιηση ace2 για θεραπεια καρδιακης, πνευμονικης και νεφρικης ασθενειας και υπερτασης
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
EP1913391A4 (en) QUANTITATIVE ASSAYS FOR PDGFR IN BODY FLUIDS
BR112014002975A2 (pt) composições de biomarcador e métodos
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA200900345A1 (ru) Замещенные ациланилиды и способы их применения
BR112013013460A8 (pt) métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total
BRPI0518086A (pt) métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
EA201690111A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
CY1105322T1 (el) Μεθοδοι και συνθεσεις για την ανιχνευση παθολογικων συμβαντων
CY1115640T1 (el) Διαγνωση και αγωγη εναντι της σχιζοφρενειας
ATE531820T1 (de) Gesundheitszustandstest
CY1125388T1 (el) Πολυπλεγμενη παραλληλη αναλυση εμπλουτισμενη σε στοχους για την αξιολογηση βιοδεικτων ογκου
CY1122202T1 (el) Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης
MX377026B (es) Biomarcadores para la progresión de enfermedades en melanoma.
WO2015049390A3 (en) Kidney disease biomarker
EP2245460A4 (en) TEST SYSTEM FOR ASSESSING ONCOGENICITY, TUMOR DEVELOPMENT AND EFFICACY OF TREATMENT
BR112015021507A2 (pt) métodos e composições para o diagnóstico de pré-eclampsia
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
EA201490576A1 (ru) Молекулярный маркер для ранней диагностики мезотелиомы плевры у пациентов и способы для анализа его экспрессии
BR112013025197A2 (pt) métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer